In bladder cancer (BC), chromosomal translocations can fuse TACC3 to FGFR3, resulting in constitutive activation of FGFR3 kinase and driving cellular transformation [13, 25–27]. This evidence concerns the gene FGFR3 and urinary bladder cancer.